spa-s-843 has been researched along with Disease-Models--Animal* in 2 studies
2 other study(ies) available for spa-s-843 and Disease-Models--Animal
| Article | Year |
|---|---|
Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis.
SPK-843, a new polyene antifungal, exhibited dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibited no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) (1.0 mg/kg) and liposomal amphotericin B (AmBisome) (8.0 mg/kg). Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus flavus; Disease Models, Animal; Dose-Response Relationship, Drug; Echinocandins; Lipopeptides; Lipoproteins; Lung Diseases, Fungal; Male; Micafungin; Mice; Polyenes; Treatment Outcome | 2008 |
Efficacy of SPK-843, a novel polyene antifungal, in a murine model of systemic cryptococcosis.
SPK-843, a new polyene antifungal, possessed efficacy in a murine model of systemic infection caused by Cryptococcus neoformans. The administration of 4.0 mg/kg SPK-843 led to better survival prolongation and fungal reduction than those observed with the administration of 0.7 mg/kg amphotericin B and 80 mg/kg fluconazole (P < 0.001), without histopathological renal changes. Topics: Animals; Antifungal Agents; Brain; Cryptococcosis; Cryptococcus neoformans; Disease Models, Animal; Female; Mice; Mice, Inbred BALB C; Polyenes | 2008 |